Topic: bispecific antibodies
Adimab is continuing a dealmaking streak with three more deal expansions, with Novartis, Regeneron and Takeda.
The action sees Daiichi pay Zymeworks $3.5 million to license an asset based on its bispecific antibody platform.
Surrozen reeled in a $50 million series B round, which will propel its antibody programs in liver disease and build out its platform into other areas.
The FDA placed a partial clinical hold on a bispecific antibody in development for acute myeloid leukemia following reports of two patient deaths.
Under the deal, AbbVie can acquire Teneobio's affiliate TeneoOne, after which it will take over the development and commercialization of the asset.